University of Washington School of Medicine

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Patient, FDA, Research, Gian Maria Annovi, Standard of care, Kinetics, AD, PD, Patent, III, II, Human, Neurodegenerative disease, ADCS, Axonal transport, News, Conference, CNS, Inflammation, Data, PHL, ThinkEquity, Mouse, AAIC, American City Business Journals, Neurology, University of Washington School of Medicine, University, Brain, Safety, Movement, European, Death, Communication, Cognition, DSMB, Pharmaceutical industry, Vaccine, Cryptocurrency, Palladium

With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.

Key Points: 
  • With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
  • Financial Results (for the quarter ending September 30, 2023)
    Cash and cash equivalents were $6.4 million.
  • Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

Metagenomi Appoints Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Research, FDA, University of Washington School of Medicine, IND, Therapy, Pathology, Acquisition, MBA, Drug development, Senior, Wellesley College, Genome, Science, DSM-IV codes, Amgen, University, True north, Bioverativ, Certified Treasury Professional, Columbia University, Patient, Five prime untranslated region, Pharmaceutical industry, Management, Economics

“I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi.

Key Points: 
  • “I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi.
  • Dr. Borges was most recently Chief Scientific Officer at Century Therapeutics, where he successfully built a multifunctional discovery and translational research organization.
  • Prior to Century, he served as Chief Scientific Officer at Cell Medica, Senior Vice President of Research at Five Prime Therapeutics, and Scientific Director in Amgen’s Therapeutic Innovation Unit.
  • As Chief Financial Officer at True North Therapeutics, Pamela completed preparations for an initial public offering before the company’s acquisition by Bioverativ.

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Patient, Rheumatology Research Foundation, Standard of care, Psoriasis, Headache, American College, VAS, Diarrhea, Research, Nausea, REM, MACR, Common, Amgen, University of Washington School of Medicine, Joint, University, AMGN, American College of Rheumatology, Nonsteroidal anti-inflammatory drug, Safety, LDA, Pain, ACR, BSA, Hospital, Body surface area, Disability, Psoriatic arthritis, Pharmaceutical industry, Medical imaging, Rheumatology

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.

Key Points: 
  • Placebo
    THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis.
  • FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years.
  • Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.
  • "These patients experienced a significant reduction in psoriatic disease activity, a crucial finding for those in the early stages of the condition."

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Retrieved on: 
Friday, November 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Standard of care, University of Washington School of Medicine, Hyperkalemia, Oxford, Pressure, Albuminuria, SGLT2, Kidney, HIV disease progression rates, Society, American Society of Nephrology, Population 1 (album), Chronic kidney disease, Phase, Boehringer Ingelheim, Clinical trial, ASN, Hypertension, Aldosterone, Risk, Kidney disease, University, Serum, ASI, CKD, Safety, End organ damage, Patient, Ingelheim am Rhein, Pharmaceutical industry, UACR, Medicine

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).

Key Points: 
  • Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).
  • “With over 1 billion people worldwide affected by these conditions, the potential to help reduce the pressure on healthcare systems and patients is immense.
  • We are proud to be leading the way in this field and are excited to move forward with the upcoming Phase III trial to further investigate the potential of this novel compound on top of standard of care including empagliflozin."
  • Hyperkalemia occurred at a rate typical for a CKD population,1 and most episodes did not require medical treatment or BI 690517 discontinuation.1

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

Retrieved on: 
Thursday, November 2, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Knowledge, Dell Medical School, University of Washington School of Medicine, SMMT, University of Colorado School of Medicine, Associate, Therapy, University, Lung cancer, Head, MD, University of Texas at Austin, Drug, University of Ottawa Heart Institute, Thyroid, Summit, Drug development, Senior, Quality of life, Lung, Disease, JAMA Otolaryngology–Head & Neck Surgery, Immunotherapy, Patient, Moses Austin, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.
  • We are very excited to welcome Laura to our team.”
    Dr. Chow remains in active clinical practice as a medical oncologist specialized in lung and head and neck cancers.
  • She joins Summit from Fate Therapeutics, where she was the Vice President of Clinical Development in Solid Tumors.
  • Chow’s experience being on the ground floor of cancer immunotherapy is unmatched,” added Dr. Allen S. Yang, Chief Medical Officer at Summit.

Horizon Air names 28-year industry veteran, Jason Berry, as president

Retrieved on: 
Friday, November 3, 2023
Alaska Airlines, Central Washington University, University of Washington School of Medicine, Heart, Boeing 737 Classic, MBA, Foster School of Business, Alaska Air Group, Air Cargo World, Business, University, Air Canada, Horizon Air, Boeing, Airline, Management, Horizon

SEATTLE, Nov. 3, 2023 /PRNewswire/ -- This week, the Horizon Air Board of Directors elected Jason Berry as president of Horizon Air.

Key Points: 
  • SEATTLE, Nov. 3, 2023 /PRNewswire/ -- This week, the Horizon Air Board of Directors elected Jason Berry as president of Horizon Air.
  • Berry replaces Joe Sprague, who is retiring as Horizon president after four years and will shift to a senior advisor role at Alaska Airlines.
  • Prior to his role at Horizon, Berry spent two years as vice president of cargo at Air Canada.
  • He started his career on the ramp while still in high school and brings years of industry experience and knowledge to his role as Horizon president.

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

Retrieved on: 
Thursday, October 26, 2023
FAAD, Laboratory, FDA, Columbia University Irving Medical Center, FARMS, SciTech, University of Washington School of Medicine, Duke University, Therapy, SDP, MD, Publication, Retinoid, Duke University School of Medicine, Bone marrow, Fenretinide, Division, Clinical trial, Internal medicine, MAB, Emory University, Malignancy, Bexarotene, University, Immediate, Safety, Cancer, International Society, Patient, Toxicity, Fred Hutchinson Cancer Research Center, Lymphoma, Vaccine, Pharmaceutical industry, Research, Dermatology, Medicine

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.

Key Points: 
  • GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.
  • The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community.
  • The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D.
  • Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity."

BrainCheck Expands First End-to-End Solution for Cognitive Care

Retrieved on: 
Tuesday, October 24, 2023
Summit Health, Alzheimer's disease, University of Washington School of Medicine, National Alzheimer's Project Act, Moca, Trial of the century, AD, Montreal Cognitive Assessment, Health information management, Medicare, Breast Cancer Awareness Month, Data, Deficit spending, D.O, Health, Research, Clinical trial, Dementia, Severity, Tablet, University, MSE, EHR, Patient, Computerize, Montreal, Cholesterol, Medical imaging, Medical device, MD, Index

AUSTIN, Texas, Oct. 24, 2023 /PRNewswire/ -- BrainCheck, Inc. launched the next generation of its comprehensive platform and unveiled its latest innovation, BrainCheck® Screen™, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts from October 24-27, ahead of National Alzheimer's Awareness Month. New research supporting BrainCheck's comprehensive digital cognitive assessment tool will also be presented at the meeting.

Key Points: 
  • "More than six million Americans have Alzheimer's disease (AD), the most common type of dementia, but unfortunately many remain undiagnosed,i" said Kim Rodriguez, CEO of BrainCheck.
  • "Early diagnosis will help close this gap, and our platform empowers providers to easily access information on patients' cognitive health by offering a unique solution that includes screening, assessment, care planning, and monitoring.
  • The latest version brings cognitive care to the next level, expanding access to our technology from any device or location, in-clinic or remote.
  • The next generation of the BrainCheck platform allows digital cognitive testing on any internet-connected device – including phones, tablets and browsers – regardless of the patient or clinician's location.

neuro42 Receives Direct Investment and Appoints Surgical Robotics Industry Pioneer Fred Moll as Strategic Advisor

Retrieved on: 
Thursday, October 5, 2023
Berkeley, Neurosurgery, Economics, Intuitive Surgical, University, Stanford University, Insightec, Robotics, ISRG, SAN, Medtech, MRI, University of Washington School of Medicine, Medical device

neuro42 also appointed Dr. Moll as strategic advisor.

Key Points: 
  • neuro42 also appointed Dr. Moll as strategic advisor.
  • “We are proud that Dr. Moll, renowned Medtech entrepreneur, has recognized our differentiated MRI-robotic technology platform and vision to change the surgical standard of care in neurosurgery, with a direct investment made to neuro42,” said Abhita Batra, Founder and Chief Strategy Officer of neuro42.
  • “We are also thrilled to welcome Dr. Moll as a strategic advisor to neuro42.
  • Earlier in his career, Dr. Moll founded and co-founded three other surgical robotics companies, including Intuitive Surgical, Inc. (ISRG), a world leader in surgical robotics, in 1995.

Premera Blue Cross Blue Shield of Alaska Improves Alaskans' Access to Behavioral Healthcare

Retrieved on: 
Tuesday, October 10, 2023
ID, University of Washington School of Medicine, Premera Blue Cross, University of Alaska Anchorage, University, Collaborative Care, Mental health, Master of Social Work, Growth, Matchmaker, Clifford Whittingham Beers, Patient, Health insurance, Nursing

ANCHORAGE, Alaska, Oct. 10, 2023 /PRNewswire/ -- Premera Blue Cross Blue Shield of Alaska today announced improvements to members' access to behavioral healthcare, which includes care for mental health conditions and substance use disorders, through new solutions that break down barriers to accessing care. This three-year initiative included developing a service to help members find an available provider and expanding the health plan's provider network.

Key Points: 
  • Millions of people are affected by behavioral health conditions every year, but despite how common these issues are, people still struggle to get care.
  • Premera is helping members get connected to care through its Matchmaker™ for Behavioral Health program.
  • Premera also expanded its behavioral health provider network in Alaska by 45 percent in the last three years to meet the increased demand for care.
  • For more information about how to find care and use a plan's benefits, visit the behavioral health care essentials page .